Results 101 to 110 of about 8,550 (230)

Novel and emerging antimicrobial strategies in the management of oral infections

open access: yesPeriodontology 2000, EarlyView.
Abstract Background Antibiotics marked a pivotal turning point in human civilization, enhancing social interactions and extending human life expectancy. In addition to their success in treating systemic infectious diseases, they have significantly improved periodontal treatment outcomes as an adjunct therapy.
Ozge Unlu, Nil Yakar, Alpdogan Kantarci
wiley   +1 more source

Expression characteristics of dual‐specificity phosphatase 2 and hypoxia‐inducible factor‐1α in acute kidney injury and preliminary study of the effect of dual‐specificity phosphatase 2 on HK‐2 cells

open access: yesExperimental Physiology, EarlyView.
ABSTRACT Acute kidney injury (AKI) is a global health problem with significant long‐term harm if the prognosis is poor. Dual‐specificity phosphatase 2 (DUSP2) is involved in key regulatory pathways in several disease processes, but its function in renal pathophysiology is unclear.
Xueqian Chu   +8 more
wiley   +1 more source

Beyond the Battlefield: Examining Acute Kidney Injury in Yemen's Humanitarian Crisis

open access: yesPublic Health Challenges, Volume 5, Issue 3, September 2026.
ABSTRACT Background Acute kidney injury (AKI) represents a growing yet under‐recognized public health threat in Yemen, where ongoing conflict has exacerbated vulnerabilities to infectious diseases and waterborne illnesses. Sepsis and severe volume depletion—secondary to diarrheal diseases such as cholera—are leading contributors to AKI incidence ...
Gamal Esam Ahmed Alsakkaf
wiley   +1 more source

Translation and Validation of the Japanese Version of the Dialysis Patient‐Perceived Exercise Benefits and Barriers Scale

open access: yesJournal of Renal Care, Volume 52, Issue 3, September 2026.
ABSTRACT Background Regular exercise is recommended for patients undergoing haemodialysis; however, participation rates remain low in Japan. Perceived benefits and barriers are key cognitive determinants of exercise behaviour, yet no validated instrument exists to assess these perceptions among Japanese patients receiving haemodialysis.
Ryota Kumakura   +5 more
wiley   +1 more source

Diagnostic Model Development for IC/BPS and Its Subtypes Using Clinical Indicators, Urinary Biomarkers, and Single‐Cell Transcriptomic Analysis

open access: yesThe FASEB Journal, Volume 40, Issue 15, 15 August 2026.
Subjects were divided into HC, NHIC, and HIC groups. Clinical Characteristics, urinary ultrasound parameters, and urinary biomarkers were collected for ML screening of predictive signatures. DEGs are identified from GEO transcriptomic data; scRNA‐seq delineates cell clusters, pseudotime trajectories and intercellular communication.
Cheng Luo   +5 more
wiley   +1 more source

Beyond Glucocorticoids: The Current Landscape and Prospects for Treating Immune Checkpoint Inhibitor‐Induced Autoimmunity

open access: yesACR Open Rheumatology, Volume 8, Issue 8, August 2026.
The rapid integration of immune checkpoint inhibitors (ICIs) into standard oncology protocols has birthed a new frontier in clinical rheumatology: immune‐related adverse events (irAEs). By disrupting the programmed cell death‐1 (PD‐1)/PD‐L1 and cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4) axes to restore antitumor T cell activity, these ...
Xizi Hu   +3 more
wiley   +1 more source

Nationwide Temporal Trends in Adverse Pregnancy Outcomes and Treatments in Systemic Lupus Erythematosus Pregnancy Over Two Decades in Sweden

open access: yesArthritis &Rheumatology, Volume 78, Issue 8, Page 1700-1709, August 2026.
Objective This nationwide descriptive study examined temporal trends in adverse pregnancy outcomes (APOs) and treatments in systemic lupus erythematosus (SLE) pregnancies in Sweden over 2003 to 2022. Methods Using nationwide Swedish registers, we identified 1,417 pregnancies of women with prevalent SLE and delivery dates in 2003 to 2022 and matched ...
Ngoc V. Nguyen   +6 more
wiley   +1 more source

Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results From the Phase 2 Randomized Trial

open access: yesArthritis &Rheumatology, Volume 78, Issue 8, Page 1692-1699, August 2026.
Objective Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE) and is partially driven by type I interferon signaling. Anifrolumab, an approved treatment for patients with SLE, has been investigated in a phase 2 trial in patients with LN receiving standard therapy (TULIP‐LN, ClinicalTrials.gov identifier ...
Andrea Fava   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy